187 related articles for article (PubMed ID: 34834371)
1. Sorafenib Repurposing for Ophthalmic Delivery by Lipid Nanoparticles: A Preliminary Study.
Bonaccorso A; Pepe V; Zappulla C; Cimino C; Pricoco A; Puglisi G; Giuliano F; Pignatello R; Carbone C
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834371
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma.
Cimino C; Sánchez López E; Bonaccorso A; Bonilla L; Musumeci T; Badia J; Baldomà L; Pignatello R; Marrazzo A; Barbaraci C; García ML; Carbone C
Int J Pharm; 2024 Jun; 660():124300. PubMed ID: 38851409
[TBL] [Abstract][Full Text] [Related]
3. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit.
Leonardi A; Bucolo C; Drago F; Salomone S; Pignatello R
Int J Pharm; 2015 Jan; 478(1):180-186. PubMed ID: 25448580
[TBL] [Abstract][Full Text] [Related]
4. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation.
Fangueiro JF; Andreani T; Fernandes L; Garcia ML; Egea MA; Silva AM; Souto EB
Colloids Surf B Biointerfaces; 2014 Nov; 123():452-60. PubMed ID: 25303852
[TBL] [Abstract][Full Text] [Related]
6. Application of lipid nanoparticles to ocular drug delivery.
Battaglia L; Serpe L; Foglietta F; Muntoni E; Gallarate M; Del Pozo Rodriguez A; Solinis MA
Expert Opin Drug Deliv; 2016 Dec; 13(12):1743-1757. PubMed ID: 27291069
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery.
Das S; Chaudhury A
AAPS PharmSciTech; 2011 Mar; 12(1):62-76. PubMed ID: 21174180
[TBL] [Abstract][Full Text] [Related]
8. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy.
Fu T; Yi J; Lv S; Zhang B
J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177
[TBL] [Abstract][Full Text] [Related]
9. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
[TBL] [Abstract][Full Text] [Related]
10. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases.
Srinivasarao DA; Lohiya G; Katti DS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jul; 11(4):e1548. PubMed ID: 30506871
[TBL] [Abstract][Full Text] [Related]
11. Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies.
Fangueiro JF; Calpena AC; Clares B; Andreani T; Egea MA; Veiga FJ; Garcia ML; Silva AM; Souto EB
Int J Pharm; 2016 Apr; 502(1-2):161-9. PubMed ID: 26921515
[TBL] [Abstract][Full Text] [Related]
12. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
Babizhayev MA
Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243
[TBL] [Abstract][Full Text] [Related]
13. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers.
El-Salamouni NS; Farid RM; El-Kamel AH; El-Gamal SS
Int J Pharm; 2015 Dec; 496(2):976-83. PubMed ID: 26498372
[TBL] [Abstract][Full Text] [Related]
14. Self Nanoemulsifying Drug Delivery System of Sorafenib Tosylate: Development and
Sandhya P; Poornima P; Bhikshapathi DVRN
Pharm Nanotechnol; 2020; 8(6):471-484. PubMed ID: 33069205
[TBL] [Abstract][Full Text] [Related]
15. Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome.
Tan G; Li J; Song Y; Yu Y; Liu D; Pan W
Acta Biomater; 2019 Nov; 99():350-362. PubMed ID: 31449929
[TBL] [Abstract][Full Text] [Related]
16. Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles.
Zhang H; Zhang FM; Yan SJ
Int J Nanomedicine; 2012; 7():2901-10. PubMed ID: 22787390
[TBL] [Abstract][Full Text] [Related]
17. Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence.
Puglia C; Santonocito D; Romeo G; Intagliata S; Romano GL; Strettoi E; Novelli E; Ostacolo C; Campiglia P; Sommella EM; Pignatello R; Bucolo C
Molecules; 2021 Aug; 26(15):. PubMed ID: 34361825
[TBL] [Abstract][Full Text] [Related]
18. Designing lipid nanoparticles for topical ocular drug delivery.
Alvarez-Trabado J; Diebold Y; Sanchez A
Int J Pharm; 2017 Oct; 532(1):204-217. PubMed ID: 28893582
[TBL] [Abstract][Full Text] [Related]
19. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
20. Solid Lipid-Polymer Hybrid Nanoparticles by In Situ Conjugation for Oral Delivery of Astaxanthin.
Wang T; Hu Q; Lee JY; Luo Y
J Agric Food Chem; 2018 Sep; 66(36):9473-9480. PubMed ID: 30130387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
